Stay updated with breaking news from Expanded Label. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones
(1) BASEL (dpa-AFX) - Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto. Read on. 1. Sickle Cell Disease Trial Blues For bluebird bio Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company's LentiGlobin gene therapy trials for sickle cell disease were temporarily suspen...
BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod Read on. 1. Bio-Path On A Steady Path Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells. In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib, on February 23...